Document is current

Article History

Received: 4 January 2026

Accepted: 24 June 2026

First Online: 27 July 2026

Ethics

Competing interests: J.S. has received honoraria for speaking and advising/consulting from AbbVie, Bausch Health, Eisai, Idorsia, Janssen, Lundbeck, Novo Nordisk, Otsuka, and the College of Physicians and Surgeons of Alberta and is supported by the Alberta Academic Medicine and Health Services Program (AMHSP). P.G., S.P., C.B., and G.G. declare no competing interests. Y.Z., O.W., and L.B. are supported by the Alberta Academic Medicine and Health Services Program (AMHSP) and have no competing interests. A.K. has received honoraria for speaking and advising/consulting from AbbVie, Bausch Health, Eisai, Elvium, Idorsia, Jazz, Lundbeck, and Otsuka. R.S.M. has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, and Atai Life Sciences. E.B. has received honoraria from Biocase for education activities in PAP. C.N.S. has received honoraria for advising/consulting from Otsuka, Diamond Therapeutics, Eisai, Idorsia, Bayer, Astellas, AbCellera and received research grants from Clairvoyant Therapeutics, Eisai, Diamond Therapeutics and the Ontario Brain Institute. Author C.N.S. is a co-Guest Editor for this Nature Mental Health special collection on Psychedelics, but was not involved in the journal’s review of, or decisions related to, this manuscript.